BCYC
Bicycle Therapeutics plcAbout BCYC
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Company
- Headquarters
- Cambridge, X0
- Employees
- 288 (2026)
- Listed
- May 23, 2019
- Exchange
- Nasdaq
- Website
- bicycletherapeutics.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #211 of 429
- P/B #328 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.28T+4.58%
- JNJJohnson & Johnson$677.9B+2.33%
- ABBVAbbVie Inc$516.6B+0.54%
- MRKMerck & Co Inc$369.5B+2.35%
- NVSNovartis AG$309.9B+1.19%
Financial summary
Related companies
About
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.